NEW YORK (GenomeWeb) – MolecularMD announced today that it will now provide Promega's Microsatellite Instability (MSI) v1.2 Analysis System as part of a larger portfolio of diagnostic and clinical research products aimed at supporting the development of oncology drugs and clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.